A medical team reviews a population-based case-control study investigating the association between a newly developed oral immunomodulator and the risk of developing drug-induced lupus erythematosus (DILE). The initial unadjusted analysis yields an odds ratio (OR) of 3.2 (95% CI: 2.4 - 4.1), suggesting a significant association. Recognizing that drug metabolism rates vary in the population, the researchers decide to stratify the study data based on the patients' hepatic acetylator phenotype. Upon re-analysis, the OR for developing DILE in the subgroup of slow acetylators is 6.1 (95% CI: 4.2 - 8.5). In contrast, the OR in the subgroup of rapid acetylators is 1.1 (95% CI: 0.7 - 1.5). Which of the following epidemiological concepts best explains the role of the acetylator phenotype in these findings?
- AConfounding
- Effect modificationAnswer
- CSelection bias
- DMeasurement bias
- ELead-time bias